Phase I Trial of Everolimus and Capecitabine in Metastatic HER2 (Record no. 27057592)

MARC details
000 -LEADER
fixed length control field 01438 a2200409 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250517150022.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201805s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1938-0666
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.clbc.2017.03.003
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Vidal, Gregory A
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20180529
245 00 - TITLE STATEMENT
Title Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Clinical breast cancer
Date of publication, distribution, etc. 10 2017
300 ## - PHYSICAL DESCRIPTION
Extent 418-426 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Administration, Oral
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Combined Chemotherapy Protocols
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Breast Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Capecitabine
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Disease-Free Survival
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Dose-Response Relationship, Drug
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Everolimus
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Maximum Tolerated Dose
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chen, Mary
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sheth, Shruti
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Svahn, Tiffany
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Guardino, Ellie
773 0# - HOST ITEM ENTRY
Title Clinical breast cancer
Related parts vol. 17
-- no. 6
-- p. 418-426
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1016/j.clbc.2017.03.003">https://doi.org/10.1016/j.clbc.2017.03.003</a>
Public note Available from publisher's website

No items available.